Aptar beats Q4 revenue, profit estimates; announces $600 mln buyback

AptarGroup

05/02/2026 22:09

Overview

Drug delivery tech firm's Q4 revenue grew 14%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company announced new $600 mln share repurchase authorization

Outlook

Aptar expects Q1 2026 adjusted EPS between $1.13 and $1.21

Company anticipates strong Pharma growth outside emergency medicine

Aptar forecasts 2026 capital investments of $260 mln to $280 mln

Result Drivers

PHARMA GROWTH - Driven by strong demand for elastomeric components and systemic nasal drug delivery technologies

BEAUTY DEMAND - Double-digit growth in Beauty segment due to increased demand for dispensing technologies

PROFITABILITY IMPACT - Less favorable product mix and higher production costs affected overall profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$963 mln
$882.21 mln (6 Analysts)
Q4 Adjusted EPS
Beat
$1.25
$1.23 (7 Analysts)
Q4 EPS
$1.13
Q4 Net Income
$74.3 mln


Press Release: ID:nBw6JcRQka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)